RecruitingNot ApplicableNCT07009093
Utility of a Mobile Application for Young Women With Breast Cancer
Sponsor
Wake Forest University Health Sciences
Enrollment
120 participants
Start Date
Apr 1, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
This study aims to evaluate the use of mobile technology as a communication tool among patients with breast cancer and measured its effect on patient-reported cancer-related distress, specifically focusing on young women as they often face unique challenges.
Eligibility
Sex: FEMALEMin Age: 18 YearsMax Age: 45 Years
Inclusion Criteria9
- Ability to understand and willingness to sign an IRB-approved informed consent
- Age ≥ 18 and ≤ 45 years at the time of consent
- Female
- Established patient at Atrium Health Wake Forest Baptist Comprehensive Cancer Center (AHWFBCCC)
- Histological confirmation of any type and stage (0-IV) of breast cancer
- Screening (baseline) NCCN Distress Thermometer score ≥ 4
- Access to a mobile device for trial purposes and an active email address
- Ability to read and understand the English language. NOTE: The Mighty Pro Application is available in English only.
- As determined by the enrolling Investigator, ability of the participant to understand and comply with study procedures for the entire length of the study
Exclusion Criteria1
- \- None
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERMighty Pro Application
Access to Mighty Pro Application
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07009093
Related Trials
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
NCT06790693219 locations
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer
NCT072146623 locations
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors
NCT05896189680 locations
E-Mindfulness Approaches for Living After Breast Cancer
NCT06748222299 locations
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT058799261224 locations